Abstract
Merck & Co is developing MK-431, the lead from a series of dipeptidyl peptidase IV inhibitors that enhance endogenous glucagon-like peptide-1 levels, for the potential treatment of type 2 diabetes. Phase III studies were initiated in the second quarter of 2004.
MeSH terms
-
Adenosine Deaminase / pharmacology
-
Adenosine Deaminase / therapeutic use*
-
Adenosine Deaminase Inhibitors*
-
Animals
-
Clinical Trials as Topic
-
Contraindications
-
Dipeptidyl Peptidase 4 / pharmacology
-
Dipeptidyl Peptidase 4 / therapeutic use*
-
Drug Industry / methods
-
Drug Industry / trends
-
Glycoproteins / antagonists & inhibitors*
-
Glycoproteins / pharmacology
-
Glycoproteins / therapeutic use*
-
Humans
-
Hypoglycemic Agents / chemistry
-
Hypoglycemic Agents / pharmacology
-
Hypoglycemic Agents / therapeutic use*
-
Protease Inhibitors / adverse effects
-
Protease Inhibitors / therapeutic use*
-
Pyrazines / adverse effects
-
Pyrazines / chemistry
-
Pyrazines / therapeutic use*
-
Sitagliptin Phosphate
-
Triazoles / adverse effects
-
Triazoles / chemistry
-
Triazoles / therapeutic use*
Substances
-
Adenosine Deaminase Inhibitors
-
Glycoproteins
-
Hypoglycemic Agents
-
Protease Inhibitors
-
Pyrazines
-
Triazoles
-
DPP4 protein, human
-
Dipeptidyl Peptidase 4
-
Adenosine Deaminase
-
Sitagliptin Phosphate